We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




PEPFAR and BD Improve African Blood Collection Safety

By LabMedica International staff writers
Posted on 18 Aug 2009
United States officials have signed a partnership agreement with Becton, Dickinson and Company (BD; Franklin Lakes, NJ, USA), launching an initiative to improve blood collection safety in clinics and hospitals in sub-Saharan Africa. More...
The aim of the pact is to protect healthcare personnel and patients in African countries from infectious agents such as human immunodeficiency virus (HIV) that are transmitted by blood.

A Memorandum of Understanding was signed in Washington on August 11, 2009 by Ambassador Elizabeth Bagley, the U.S. Department of State special representative for global partnerships (Washington DC, USA), and Gary M. Cohen, executive vice president of BD.

Safer blood collection has become critical in sub-Saharan nations and other emerging African countries, which are severely impacted by the HIV/AIDS pandemic. Access to HIV treatment in these countries significantly increased in recent years and consequently has expanded the quantity of blood drawing for HIV screening and monitoring tests.

The three-year initiative--which may be extended up to two additional years--is scheduled to begin in Kenya and expand to include up to four additional U.S. President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. It will ultimately support in-service training for as many as 10,000 healthcare workers. When fully implemented, the monitoring component of the initiative aims to track as many as two million blood-draws within each participating country.

''The program will help hospital and clinical personnel improve their blood-drawing procedures and specimen handling, processes that are critical to the proper management of HIV/AIDS patients,'' said the State Department (Washington DC, USA) release. In addition, "… [it] will help prevent needle stick injuries by establishing or enhancing needle stick-injury surveillance. These monitoring measures can identify practices that pose risks to health workers and patients.''

Ministries of Health in participating countries will develop individualized policies, guidelines, and standard operating procedures for blood drawing and specimen handling.

Related Links:
U.S. Global Partnership Initiative, the Department of State
Becton, Dickinson and Company
PEPFAR


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
BKE-B
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.